Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Publication

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Journal Paper/Review - Jun 20, 2018

Beumer Jan H, Boku Narikazu, Muneoka Katsuki, Arnold Dirk, Zhang Li, Mathijssen Ron H, Kim Tae Won, Diasio Robert, Milano Gerard, Tanigawara Yusuke, Allegra Carmen, Chu Edward, Jörger Markus

Citation

Beumer J, Boku N, Muneoka K, Arnold D, Zhang L, Mathijssen R, Kim T, Diasio R, Milano G, Tanigawara Y, Allegra C, Chu E, Jörger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2018

Type

Journal Paper/Review (English)

Journal

Clin Pharmacol Ther 2018

Publication Date

Jun 20, 2018

Issn Electronic

1532-6535

Brief description/objective

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.